Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data
CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.What Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.“There is a lot of need for vaccines ou
Join Tiger Brokers with me and receive stock vouchers of up to 1 million!https://www.tigerbrokers.com.sg/activity/market/2021/7th-anniversary/*4M1FJW-index.html?feature=Message&platform=android&lang=en_US&skin=1&edition=fundamental&invite=4M1FJW&share=WhatsAPP